EUCTR2005-000802-30-IT进行中（未招募）不适用
Phase II study of the combination of Bevacizumab (rhuMab VEGF) plus Capecitabine with pre-operative standard radiotherapy in patients with locally advanced rectal cancer.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- ROCHE
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients with histologically or cytologically confirmed diagnosis of rectal carcinoma, who are subject to surgery for rectal cancer and are considered to have benefit from pre-operative combined chemo-radiotherapy, (i.e.: stage cT3, cT4, fixative tumors, tumors primarily inoperable). 2. Age >= 18 3. ECOG Performance Status 0-1 (Appendix III) 4. Life expectancy of at least 12 weeks 5. Measurable and/or evaluable lesions according to RECIST criteria 6. Laboratory requirements: ` Neutrophils >= 1.5 x 109/L and Platelets >= 100 x 109/L ` Total bilirubin <= 1.5 time the upper-normal limits (UNL) of the Institutional normal values and ASAT (SGOT) and/or ALAT (SGPT) <= 2.5 x UNL, or <= 5 x UNL in case of liver metastases, alkaline phosphatase <= 2.5 x UNL, <= 5 x UNL in case of liver metastases. ` Creatinine clearance >50 mL/min or serum creatinine <= 1.5 x UNL) ` Urine dipstick of proteinuria <2+. Patients discovered to have >= 2+ proteinuria on dipstick urinalysis at baseline, should undergo a 24-hour urine collection and must demonstrate <=1 g of protein/24 hr. 7. Written informed consent. 8. Patients must be accessible for treatment and follow up. Patients registered on this trial must be treated and followed at the participating Center.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Prior radiotherapy or chemotherapy for rectal cancer. 2. Untreated brain metastases or spinal cord compression or primary brain tumours. 3. History or evidence upon physical examination of CNS disease unless adequately treated (e.g., seizure not controlled with standard medical therapy or history of stroke). 4. History of inflammatory bowel disease and/or acute/subacute bowel occlusion. 5. Serious, non-healing wound, ulcer, or bone fracture. 6. Evidence of bleeding diathesis or coagulopathy. 7. Uncontrolled hypertension. 8. Clinically significant (i.e. active) cardiovascular disease for example cerebrovascular accidents (≤6 months), myocardial infarction (≤6 months), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication. 9. Current or recent (within 10 days prior to study treatment start) ongoing treatment with anticoagulants for therapeutic purposes. 10. Chronic, daily treatment with high-dose aspirin (>325 mg/day) or other medications known to predispose to gastrointestinal ulceration. 11. Treatment with any investigational drug within 30 days prior to enrolment. 12. Patients with known allergy to Chinese hamster ovary cell proteins, or any of the components of the study medications 13. Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal and squamous cell carcinoma or cervical cancer in situ 14. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start, or anticipation of the need for major surgical procedure during the course of the study. 15. Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, or inability to take oral medication. 16. Pregnant or lactating women. Women of childbearing potential with either a positive or no pregnancy test at baseline. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential. Sexually active males and females (of childbearing potential) unwilling to practice contraception during the study.
研究者
相似试验
进行中（未招募）
不适用
Phase II Study of the Combination of Bevacizumab (rhuMAb VEGF) and Oxaliplatin plus Capecitabine (XELOX) in Patients with Advanced Colorectal CancerEUCTR2005-001012-41-ITROCHE
进行中（未招募）
不适用
Phase II study of the combination of bevacizumab plus pemetrexed and carboplatin as first-line therapy in patients with malignant pleural mesothelioma - NDHistologically proven diagnosis of malignant pleural mesothelioma.MedDRA version: 9.1Level: LLTClassification code 10059518Term: Pleural mesothelioma malignantEUCTR2006-004429-27-ITISTITUTO CLINICO HUMANITAS
已完成
不适用
Phase II Study of Bevacizumab in Combination with First-line Platinum-Doublet Chemotherapy in Non-squamous NSCLC Patients with Asymptomatic Untreated Brain Metastases.non-small cell lung cancerJPRN-UMIN000009828Osaka Prefectural Medical Center for Respiratory and Allergic Diseases25
已完成
2 期
Phase II Study of Bevacizumab in Combination with Carboplatin plus oral S1 in Chemo-Naive Patients with Non-Squamous Non-Small-Cell Lung CancerChemo-Naive Patients with Non-Squamous Non-Small-Cell Lung CancerJPRN-UMIN000003698Hyogo Cancer Center,Depatrment of Thoracic Oncology45
进行中（未招募）
不适用
Phase I-II Study of the Combination of Bevacizumab (rhuMAb VEGF) and Erlotinib (EGFR TKI) plus Oxaliplatin and Capecitabine (XELOX) in Patients with Metastatic Colorectal Cancer: XELOX-TARAV study - XELOX-TARAVEUCTR2005-005548-21-ITCONSORZIO ONCOTECH